Sector News

Moderna Appoints Tal Zaks, Former Head of Sanofi Global Oncology, as Chief Medical Officer

March 17, 2015
Life sciences
/PRNewswire/ – Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ across a range of therapeutic applications, announced today that Tal Zaks, M.D., Ph.D., will join Moderna’s executive leadership team as chief medical officer, effective March 16.
 
Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all aspects of oncology drug discovery, development and commercialization.
 
“Moderna holds an unprecedented financial position among pre-clinical biotech companies, with $900 million on its balance sheet and strategic agreements with three industry leaders: AstraZeneca, Alexion and Merck,” said Stephane Bancel, chief executive officer of Moderna. “As we prepare to initiate several clinical trials in the coming quarters, we require an exceptional chief medical officer, someone with a track record of success in clinical development combined with strong business acumen. Tal is that leader. He has a unique ability to think outside the box and execute for business results. We are delighted that he chose to join Moderna.”
 
“I am thrilled to be joining Moderna and be at the forefront of translating innovative science into real medicines for patients,” said Dr. Zaks. “I’ve been impressed with the potential of messenger RNA Therapeutics to expand and accelerate drug development for a wide range of unmet medical needs and I look forward to working with the leadership team, our partners and our ventures to fulfill this vision.”
 
Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr. Zaks is associate professor of medicine at the University of Pennsylvania, and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers.
 
Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.
 
Source: Moderna Therapeutics

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend